Ratnakar Securities Pvt. Ltd.

BIOCON LTD.

NSE : BIOCONBSE : 532523ISIN CODE : INE376G01013Industry : Pharmaceuticals & DrugsHouse : Private

BSE364.204.85 (+1.35 %)

PREV CLOSE ( ) 359.35

OPEN PRICE ( ) 360.45

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 148221

TODAY'S LOW / HIGH ( )360.30 366.35

52 WK LOW / HIGH ( )290.8 405.9

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 29-11 1978

Management Info

Kiran Mazumdar-Shaw - Chairman Siddharth Mittal - Managing Director

Registered Office

Address 20th Km,Hosur Road,Electronic City,
Bengaluru,
Karnataka-560100

Phone 080 2808 2808

Email corporate.communications@biocon.com

Website www.biocon.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE

NEWS

08Aug Biocon reports 90% fall in Q1 consolid
Biocon has reported result for first quarter ended June 30, 2025 (Q1FY26..

08Aug Biocon gets nod to enter into agreemen
Biocon has received approval to enter into a power purchase agreement an..

08Aug Biocon informs about informs about pre
Pursuant to Regulation 30 of the Securities and Exchange Board of India..

08Aug Biocon declines on reporting 90% fall
Biocon is currently trading at Rs. 354.25, down by 10.35 points or 2.84%..

23Jul Bioconâ€™s arm launches Nepexto in Aus
Bioconâ€™s subsidiary -- Biocon Biologics (BBL) has launched Nepexto, a..

Financials

in Millions

	QTR Jun 25	ANNUAL 25
Net Profit	-83	6093
Gross Profit	-76	6609
Operating Profit	819	4181
Net Sales	5371	22426

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Pfizer (BSE) 5759.70 (8.15%)	M.Cap ( in Cr)26349.32
Neuland Laboratories (BSE) 13535.05 (2.04%)	M.Cap ( in Cr)17365.32
Astrazeneca Pharma I (BSE) 8413.05 (1.47%)	M.Cap ( in Cr)21032.63
Sanofi Cons. Health (BSE) 5242.55 (1.56%)	M.Cap ( in Cr)12073.92
Eris Lifesciences (BSE) 1734.15 (2.91%)	M.Cap ( in Cr)23620.30

Shareholding Pattern

	FI/BANKS/INSURANCE	6.79%
	PROMOTERS	54.45%
	NON-INSTITUTION	16.68%
	MUTUAL FUNDS/UTI	15.24%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
ICICI Pru Pharma He...	5.02
Tata Nifty MidSmall...	3.61
Motilal Oswal Nifty...	3.59
Bajaj Finserv Healt...	3.51
Nippon India Focuse...	2.95
NJ Arbitrage Fund-Reg(G)	2.93

attention investors
kyc
ipo
ibt trading
KYC & KRA Status Awareness

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

Ratnakar Securities

Smart Quotes

BIOCON LTD.

Filing complaints on SCORES Easy & quick

RISK DISCLOSURES ON DERIVATIVES